Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.69 |
| ▸ | EYA3 | Q99504 | 2/20 | 0.69 |
| ▸ | TTR | P02766 | 1/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.61 |
| ▸ | THRA | P10827 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 2/20 | 0.58 |
| ▸ | SIRT3 | Q9NTG7 | 7/20 | 0.56 |
| ▸ | KDM5A | P29375 | 3/20 | 0.55 |
| ▸ | KDM7A | Q6ZMT4 | 2/20 | 0.55 |
| ▸ | KDM4A | O75164 | 2/20 | 0.54 |
| ▸ | ING2 | Q9H160 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9347277 | 0.98 | PTPN1 (0.67) | PTPN1EYA3TTRNR1H4THRA | |
| SCHEMBL18415631 | 0.90 | PTPN1 (0.61) | PTPN1EYA3TTRNR1H4THRA | |
| SCHEMBL27992957 | 0.89 | EYA3 (0.80) | PTPN1EYA3TTRNR1H4THRA | |
| Hydrochloric Acid SCHEMBL9347221 | 0.89 | CYP2C9 (0.58) | PTPN1EYA3TTRNR1H4THRA | |
| SCHEMBL25389924 | 0.88 | EYA3 (0.82) | PTPN1EYA3TTRNR1H4THRA | |
| SCHEMBL31314625 | 0.87 | EYA3 (0.67) | PTPN1EYA3TTRNR1H4THRA | |
| SCHEMBL2943743 | 0.87 | PTPN1 (0.67) | PTPN1EYA3TTRNR1H4THRA | |
| SCHEMBL18407419 | 0.86 | CYP2C9 (0.58) | PTPN1EYA3TTRNR1H4THRA | |
| SCHEMBL4670184 | 0.84 | EYA3 (0.66) | PTPN1EYA3TTRNR1H4THRB | |
| SCHEMBL4501314 | 0.84 | PTPN1 (0.60) | PTPN1EYA3TTRNR1H4THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397341-B1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1397341-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | claimed |
| US-6589970-B2 | This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: | WYETH | 2003-07-08 | — | — | US | claimed |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-03-06 | — | — | US | claimed |
| WO-2003000649-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | claimed |
| US-7754747-B2 | Oxazolo-naphthyl acids | WYETH LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7534894-B2 | Biphenyloxy-acids | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1397341-B1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1781645-A1 | OXAZOLO-NAPHTHYL ACIDS AS PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1(PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES | Wyeth (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1667959-A1 | BIPHENYLOXY-ACIDS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060052348-A1 | Oxazolo-naphthyl acids | WYETH (US) | 2006-03-09 | — | — | US | disclosed |
| WO-2006023865-A1 | OXAZOLO-NAPHTHYL ACIDS AS PLAMINOGEN ACTIVATOR INHIBTOR TYPE-1 (PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060020003-A1 | Biphenyloxy-acids | WYETH (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2005030702-A1 | BIPHENYLOXY-ACIDS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1397341-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6589970-B2 | This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: | WYETH | 2003-07-08 | — | — | US | disclosed |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-03-06 | — | — | US | disclosed |
| WO-2003000649-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052348-A1 | Oxazolo-naphthyl acids | SERPINE1, SERPINB1, SERPINC1 | PTPN1 1585/4885EYA3 1518/4885TTR 1086/4885 |
| US-20060020003-A1 | Biphenyloxy-acids | AHR, ARNT, NR1H4 | PTPN1 1495/4885EYA3 1493/4885TTR 2868/4885 |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | SERPINC1, F11, SERPINE1 | PTPN1 885/4885EYA3 3991/4885TTR 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.